Triazolo Quinoxaline Derivatives Glucocorticoid Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic glucocorticoid treatment for inflammatory diseases is hindered by severe adverse effects such as insulin resistance, diabetes, hypertension, glaucoma, depression, osteoporosis, and adrenal suppression, necessitating the development of novel anti-inflammatory drugs with reduced side effects.
Innovation Solution
Development of novel compounds that act as potent modulators of the glucocorticoid receptor, selectively favoring transrepression over transactivation to minimize adverse effects while maintaining anti-inflammatory efficacy, as represented by specific chemical structures defined by general formula (I).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids are used to treat inflammatory diseases, then anti-inflammatory effects are achieved, but severe adverse effects occur
Solution Approach 1:
The patent segments the glucocorticoid receptor's functional pathways into transactivation and transrepression mechanisms. By designing compounds that selectively modulate these separate pathways, the invention achieves anti-inflammatory effects through transrepression while minimizing adverse effects associated with transactivation, thus resolving the contradiction between efficacy and safety
Solution Approach 2:
The patent applies local quality by creating glucocorticoid receptor modulators with selective action on specific cellular pathways. The compounds exhibit different functional properties in different biological contexts - promoting anti-inflammatory transrepression while avoiding pro-adverse effect transactivation, thereby achieving localized therapeutic benefit without systemic harm
2Ease of operation
If glucocorticoids are discontinued abruptly, then treatment is simplified, but severe withdrawal symptoms occur
Solution Approach 1:
The patent develops novel glucocorticoid receptor modulators that act as controlled, temporary therapeutic agents. These compounds provide sufficient anti-inflammatory effect during the acute phase without causing long-term adrenal suppression, allowing for cleaner discontinuation and reduced withdrawal symptoms compared to traditional long-acting glucocorticoids
3Object-affected harmful factors
If partial agonists or selective glucocorticoid receptor modulators are developed, then adverse effects are reduced, but therapeutic efficacy may be compromised
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical structures of glucocorticoid receptor modulators to optimize their selectivity profile. By adjusting molecular parameters and substitution patterns, the invention achieves compounds with enhanced transrepression selectivity that maintain or improve therapeutic efficacy while reducing adverse effects
Data Source
AI summary
The present invention relates to compounds according to general formula (I)which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.